Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Value of Information | Infectious Diseases | State-Transition | Policy/Regulation | Economics/Finance | North America | Europe -
ArticlePublication 2020Perceptions of COVID-19 around the World
This study evaluates public risk perception of COVID-19 around the world in ten countries across …
This study evaluates public risk perception of COVID-19 around the world in ten countries across Europe, America, and Asia. They found that significant predictors of risk perception included personal experience with the virus, individualistic and prosocial values, hearing about the virus from friends and family, trust in government, science, and medical professionals, personal knowledge of government strategy, and personal and collective efficacy. Although there was substantial variability across cultures, individualistic worldviews, personal experience, prosocial values,…
Preferences/Values | Risk Analysis | Infectious Diseases | Decision Psychology | Culture/Society | Health/Medicine | Global -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Government/Law | North America -
ArticlePublication 2020Valuing COVID-19 Mortality Risk
In this article, the author evaluates whether conventional estimates of the value per statistical life …
In this article, the author evaluates whether conventional estimates of the value per statistical life (VSL) in the United States (about $10 million) are appropriate for evaluating policies that affect risk of COVID-19. This estimate may be too large, because: (1) VSL estimates marginal values but COVID-19 risks can be non-marginal; (2) VSL is estimated for the average resident, but COVID-19 mortality is concentrated among the elderly; and (3) the pandemic has caused substantial losses…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Government/Law | Global -
ArticlePublication 2021COVID and the Age–VSL Relationship
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions …
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions in analyses of lockdowns and other policies. Many rely on a population-average estimate of the value per statistical life (VSL); others adjust VSL for life expectancy at the age of death. The article explores the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain; these uncertainties in turn may affect whether the…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Government/Law | Health/Medicine | North America -
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Mathematical Models | Dynamic Transmission | Calibration/Validation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Preferences/Values | Value of Information | Infectious Diseases | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Preferences/Values | Value of Information | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Economics/Finance | Education/Labor | Health/Medicine